This inventor holds 6 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 5 EPO patents. Top assignees: Jiangsu Nhwaluokang Pharmceutical Research and Development Co., Ltd., Jiangsu Nhwaluokang Pharmaceutical Research and Development Co., Ltd., Other. Active years: 2017-2023.
Company Filing History:
4 out of 4 
1 out of 1 
1 out of 834,411 Years Active: 2017-2023
Title: Qingeng Li: Innovator in Pharmaceutical Chemistry
Introduction
Qingeng Li is a notable inventor based in Chongqing, China. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 6 patents. His work primarily focuses on the development of novel compounds with therapeutic applications.
Latest Patents
One of his latest patents is for a crystalline form of ethyl (S)-3-(8-bromo-1-methyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,2-a][1,4]diazepin-4-yl)propanoate hydrochloride. This invention provides a crystalline form of a benzodiazepine derivative hydrochloride, along with a method for its preparation and a pharmaceutical composition comprising the crystal form. Another significant patent is related to an etomidate derivative and its intermediates, which showcases good anesthetic activity, rapid onset, and a favorable safety profile.
Career Highlights
Qingeng Li has worked with Jiangsu Nhwaluokang Pharmaceutical Research and Development Co., Ltd., where he has contributed to various innovative projects. His expertise in pharmaceutical research has led to advancements in anesthetic compounds and their formulations.
Collaborations
Throughout his career, Qingeng Li has collaborated with notable colleagues, including Tao Wang and Lingguo Zeng. These partnerships have fostered a collaborative environment that enhances the innovation process.
Conclusion
Qingeng Li's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as a significant innovator in the field. His work continues to impact the development of effective therapeutic agents.